ReviewCurrent oncology reports2025
Chemotherapeutic Drug-Antibody Conjugates (ChemoBodies): Recent Advances and Future Directions.
Review in Current oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Quinoline-Based Scaffolds in Anticancer Drug Discovery: Molecular Targets, Synthetic Strategies, and Biological Advances.ChemMedChem · 2026Review
- Modular Assembly of Bioconjugates Enabled by a Pyridine-Based Chemoselective Sequential Conjugation Platform.Angewandte Chemie (International ed. in English) · 2026Article
- Radioligand-Antibody Conjugates: Integrating Antibody Engineering, Chelator Chemistry, and Radioligands for Precision Theranosis.Molecular diagnosis & therapy · 2026Review
- Mechanisms of resistance to antibody-drug conjugates in bladder cancer.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purpose of reviewChemoBodies, also known as Antibody Drug Conjugate (ADCs), are one of the fastest growing classes of biopharmaceuticals with great therapeutic potential in solid and hematological tumors, with 14 US-FDA products till July 2025, and hundreds are in clinical trials. The purpose of this review is to map each component of ChemoBodies, like antibodies and their novel engineered fragments, next-generation Chemo therapeutic drugs (Payloads), Linkers, and unique conjugation Chemistry used to develop ChemoBodies. RECENT
findingsAfter analyzing the components of approved ChemoBodies, the antibodies are mainly used to target hematological tumors (CD33, CD22, CD19, CD79b, BCMA, CD30), and solid tumors (HER2, TROP2, Tissue Factor, Folate receptor Alpha, and c-Met). Which is commonly conjugated via succinimide and maleimide chemistry to DNA-damaging agents (SG3199, Calicheamicin), Microtubule inhibitors (DM1, DM4, MMAE, MMAF), and Topoisomerases I inhibitors (DxD, SN-38). Current advancements in antibody engineering, conjugation chemistry, and novel payloads hope to overcome the challenges associated with current ChemoBodies. ChemoBody, also known as Antibody-Drug Conjugate, represents one of the promising classes of therapeutics in the treatment of Solid and haematological cancers. In this review, we summarized all the technologies employed in the development of the US-FDA-approved and under clinical trial ChemoBody molecules.
Indexed as
Identifiers
41123838What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.